CMBA
CLBT icon

C.M. Bidwell & Associates’s Cellebrite CLBT Stock Holding History

C.M. Bidwell & Associates’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-37
Closed -$815 – 460
2024
Q4 		$815 Hold
37
– – ﹤0.01% 432
2024
Q3 		$623 Hold
37
– – ﹤0.01% 455
2024
Q2 		$442 Hold
37
– – ﹤0.01% 447
2024
Q1 		$410 Buy
+37
New +$378 ﹤0.01% 458

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

C.M. Bidwell & Associates's CLBT Position: Q1 2025 in Review

C.M. Bidwell & Associates sold out of Cellebrite (CLBT) in Q1 2025, closing a stake of 37 shares — an estimated $815 sold.

C.M. Bidwell & Associates first reported a position in CLBT in Q1 2024 and held it in 4 quarters. The position peaked at $815 in Q4 2024. 199 funds tracked by Wall St. Rank hold CLBT as of Q1 2025.

  • C.M. Bidwell & Associates reported no remaining Cellebrite position as of Q1 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 37 Cellebrite shares in Q1 2025, an estimated $815.
  • C.M. Bidwell & Associates first reported a position in Cellebrite in Q1 2024 and held it in 4 quarters.
  • C.M. Bidwell & Associates's Cellebrite position peaked at $815 in Q4 2024.
  • 199 funds tracked by Wall St. Rank held Cellebrite as of Q1 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2025, filed 15 May 2025.